PMID- 24299427
OWN - NLM
STAT- MEDLINE
DCOM- 20141201
LR  - 20221207
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 16
IP  - 4
DP  - 2014 Apr
TI  - Impact of Roux-en-Y gastric bypass on metabolic syndrome and insulin resistance 
      parameters.
PG  - 262-5
LID - 10.1089/dia.2013.0249 [doi]
AB  - BACKGROUND: Metabolic syndrome (MetS) is a complex association of clustering 
      metabolic factors that increase risk of type 2 diabetes mellitus (T2DM) and 
      cardiovascular disease. Surgical treatment has become an important tool to 
      achieve its control. The aim of this study was to evaluate the impact of 
      Roux-en-Y gastric bypass (RYGB) on MetS and its individual components, clinical 
      characteristics, and biochemical features. SUBJECTS AND METHODS: The study is a 
      retrospective cohort of 96 subjects with MetS who underwent RYGB and were 
      evaluated at baseline and after surgery. Clinical and biochemical features were 
      analyzed. RESULTS: After surgery, significant rates of resolution for MetS 
      (88.5%), T2DM (90.6%), hypertension (85.6%), and dyslipidemias (54.2%) were 
      found. Significant decreases in levels of fasting glucose, fasting insulin, 
      hemoglobin A1c, low-density lipoprotein, and triglycerides and an increase in 
      high-density lipoprotein level were also shown. The decrease in insulin 
      resistance evaluated by homeostasis model assessment (HOMA-IR) was consistent. 
      MetS resolution was associated with postoperative glycemic control, decreases in 
      levels of fasting glucose, hemoglobin A1c, HOMA-IR, and triglycerides and in 
      antihypertensive usage, and percentage weight loss. CONCLUSIONS: This study found 
      high rates of resolution for MetS, T2DM, hypertension, and dyslipidemias after 
      RYGB in obese patients. This finding was consistent with current literature. 
      Hence RYGB should be largely indicated for this group of subjects as it is a safe 
      and powerful tool to achieve MetS control.
FAU - Cazzo, Everton
AU  - Cazzo E
AD  - 1 Department of Surgery, State University of Campinas , Campinas, Sao Paulo, 
      Brazil .
FAU - Gestic, Martinho Antonio
AU  - Gestic MA
FAU - Utrini, Murillo Pimentel
AU  - Utrini MP
FAU - Machado, Ricardo Rossetto
AU  - Machado RR
FAU - Geloneze, Bruno
AU  - Geloneze B
FAU - Pareja, Jose Carlos
AU  - Pareja JC
FAU - Chaim, Elinton Adami
AU  - Chaim EA
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20131203
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/*metabolism/prevention & control
MH  - Fasting
MH  - Female
MH  - Follow-Up Studies
MH  - *Gastric Bypass
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - *Insulin Resistance
MH  - Length of Stay
MH  - Male
MH  - Metabolic Syndrome/*metabolism/prevention & control
MH  - Middle Aged
MH  - Obesity, Morbid/*metabolism/physiopathology/*surgery
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Triglycerides
MH  - Weight Loss
PMC - PMC3952524
EDAT- 2013/12/05 06:00
MHDA- 2014/12/15 06:00
PMCR- 2015/04/01
CRDT- 2013/12/05 06:00
PHST- 2013/12/05 06:00 [entrez]
PHST- 2013/12/05 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - 10.1089/dia.2013.0249 [pii]
AID - 10.1089/dia.2013.0249 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2014 Apr;16(4):262-5. doi: 10.1089/dia.2013.0249. Epub 
      2013 Dec 3.